UAS regulatory sequences drive expression of wild type Hsap\TARDBP tagged at the C-terminal end with YFP.
Overexpression of Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa driven in the adult retina by Scer\GAL4GMR.PU causes a neurodegeneration phenotype, with visible depigmentation.
Overexpression of Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa driven in motor neurons by Scer\GAL4Toll-6-D42 in larvae results in locomotor dysfunction (significant increase in the amount of time taken for the larva to turn from dorsal side and resume crawling on the ventral side).
Ectopic expression of Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa under the control of Scer\GAL4GMR.PU results in an age-dependent depigmentation phenotype in the adult eye indicative of neurodegeneration.
Ectopic expression of Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa under the Scer\GAL4Toll-6-D42 driver significantly lengthens the time it takes for larvae to roll over in a turning assay and reduces adult life span compared to wild-type.
Ectopic expression of Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa under the control of Scer\GAL4Toll-6-D42 results in significantly increased number of satellite boutons and significantly decreased density of futsch positive loops on synaptic boutons on neuromuscular junctions of third instar larvae compared to wild-type controls.
Expression of Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa in motor neurons under the control of Scer\GAL4D42 is lethal at the pupal or pharate adult stage. Few pharate adults eclose but cannot extend their wings. Larvae expressing Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa display locomotor dysfunction in turning assays. Treatment with pioglitazone results in improved larval locomotor function and the survival of the animals to adulthood. However, pioglitazone-treatment is not effective at improving the lifespan of the transgenic adults.
Expression of Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa in glia under the control of Scer\GAL4repo causes locomotor function abnormalities. Pioglitazone-treatment mitigates the locomotor dysfunction phenotype. However, pioglitazone-treatment is not effective at improving the lifespan of the transgenic adults expressing Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa in glia.
Muscle-specific expression of Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa using Scer\GAL4BG487 results in larval locomotor defects which is not mitigated by pioglitazone-treatment.
This expression results in a decreased adult lifespan compared to controls.
Expression of Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa in the eye under the control of Scer\GAL4GMR.PF has no visible phenotype in the eye at 25[o]C in 0-3 day old flies but visible loss of pigmentation is seen at 5 days old and worsens with age. Cell loss and neurodegeneration is seen in retinal sections. When the temperature is increased to 29[o]C visible retinal neurodegeneration can be seen in 1-2 day old flies.
Expression of Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa under the control of Scer\GAL4D42 results in a decreased number of boutons in the larval neuromuscular junction. The number of synaptic vesicles is also reduced compared to wild type, and supernumerary satellite boutons are present. The number of axonal branches is reduced.
Expression of Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa under the control of Scer\GAL4D42 results in locomotor defects in third instar larvae. Crawling larvae rolled ventral side up take longer to turn back to dorsal side up.
78% of flies expressing Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa under the control of Scer\GAL4D42 fail to live to 30 days at 18[o]C, compared to only 30% of controls. Very few flies survive to adulthood at 25[o]C.
Flies expressing Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa under the control of Scer\GAL4D42 exhibit a progressive decline in their ability to climb at 18[o]C. At 2 days old 76.3% of flies are able to climb compared to 94.3% of controls. By 30 days old only 3.1% of flies are able to climb compared to 25% of controls.
Expression of Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa under the control of Scer\GAL4D42 does not result in motor neuron apoptosis in the larval ventral ganglia.
Expression of Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa under the control of Scer\GAL4D42 results in a dramatic loss of motor neurons in the adult thoracic ganglia.
Hsap\TARDBPUAS.YFP.cEa, Scer\GAL4GMR.PU has visible phenotype, enhanceable by Pabp255
Hsap\TARDBPUAS.YFP.cEa, Scer\GAL4GMR.PU has abnormal neuroanatomy | adult stage phenotype, enhanceable by Pabp255
Hsap\TARDBPUAS.YFP.cEa, Scer\GAL4Toll-6-D42 has abnormal locomotor behavior | larval stage phenotype, enhanceable by Pabp255
Hsap\TARDBPUAS.YFP.cEa, Scer\GAL4GMR.PU has abnormal eye color | adult stage phenotype, enhanceable by Fmr1GD1288, Scer\GAL4GMR.PU
Hsap\TARDBPUAS.YFP.cEa, Scer\GAL4GMR.PU has abnormal eye color | adult stage phenotype, enhanceable by Fmr1Δ50M/Fmr1[+]
Hsap\TARDBPUAS.YFP.cEa, Scer\GAL4Toll-6-D42 has abnormal locomotor behavior | third instar larval stage phenotype, enhanceable by Fmr1GD1288, Scer\GAL4Toll-6-D42
Hsap\TARDBPUAS.YFP.cEa, Scer\GAL4Toll-6-D42 has abnormal locomotor behavior | third instar larval stage phenotype, enhanceable by Fmr1Δ50M/Fmr1[+]
Hsap\TARDBPUAS.YFP.cEa, Scer\GAL4GMR.PF has visible | adult stage | heat sensitive phenotype, enhanceable by Prosβ21.UAS, Scer\GAL4GMR.PF
Hsap\TARDBPUAS.YFP.cEa, Scer\GAL4Toll-6-D42 has abnormal locomotor behavior | third instar larval stage phenotype, enhanceable by TBPHGD6943, Scer\GAL4Toll-6-D42
Hsap\TARDBPUAS.YFP.cEa, Scer\GAL4Toll-6-D42 has abnormal locomotor behavior | third instar larval stage phenotype, suppressible by Fmr1UAS.YFP, Scer\GAL4Toll-6-D42
Hsap\TARDBPUAS.YFP.cEa, Scer\GAL4Toll-6-D42 has short lived phenotype, suppressible by Fmr1UAS.YFP, Scer\GAL4Toll-6-D42
Hsap\TARDBPUAS.YFP.cEa, Scer\GAL4Toll-6-D42 has abnormal neuroanatomy | third instar larval stage phenotype, suppressible by Fmr1UAS.YFP, Scer\GAL4Toll-6-D42
Hsap\TARDBPUAS.YFP.cEa, Scer\GAL4GMR.PU has abnormal eye color | adult stage phenotype, suppressible by Fmr1UAS.YFP, Scer\GAL4GMR.PU
Hsap\TARDBPUAS.YFP.cEa, Scer\GAL4Toll-6-D42 has abnormal neuroanatomy | larval stage phenotype, suppressible by futschEP1419, Scer\GAL4Toll-6-D42
Hsap\TARDBPUAS.YFP.cEa, Scer\GAL4Toll-6-D42 has abnormal locomotor behavior | larval stage phenotype, suppressible by futschEP1419, Scer\GAL4Toll-6-D42
Hsap\TARDBPUAS.YFP.cEa, Scer\GAL4Toll-6-D42 has short lived phenotype, suppressible by futschEP1419, Scer\GAL4Toll-6-D42
Hsap\TARDBPUAS.YFP.cEa, Scer\GAL4GMR.PF has visible | adult stage | heat sensitive phenotype, suppressible | partially by Hsap\HSPA1LUAS.cWa, Scer\GAL4GMR.PF
Hsap\TARDBPUAS.YFP.cEa, Scer\GAL4GMR.PF has visible | adult stage | heat sensitive phenotype, suppressible by BacA\p35UAS.cHa, Scer\GAL4GMR.PF
Hsap\TARDBPUAS.YFP.cEa, Scer\GAL4Toll-6-D42 has abnormal locomotor behavior | larval stage phenotype, non-suppressible by futschHMS02000, Scer\GAL4Toll-6-D42
Eip75BΔ51/Eip75B[+], Hsap\TARDBPUAS.YFP.cEa, Scer\GAL4Toll-6-D42 has abnormal locomotor behavior | third instar larval stage phenotype
Hsap\TARDBPUAS.YFP.cEa, Scer\GAL4GMR.PU has eye phenotype, enhanceable by Pabp255
Hsap\TARDBPUAS.YFP.cEa, Scer\GAL4GMR.PU has eye | adult stage phenotype, enhanceable by Fmr1GD1288, Scer\GAL4GMR.PU
Hsap\TARDBPUAS.YFP.cEa, Scer\GAL4GMR.PU has eye | adult stage phenotype, enhanceable by Fmr1Δ50M/Fmr1[+]
Hsap\TARDBPUAS.YFP.cEa, Scer\GAL4GMR.PF has eye | heat sensitive phenotype, enhanceable by Prosβ21.UAS, Scer\GAL4GMR.PF
Hsap\TARDBPUAS.YFP.cEa, Scer\GAL4Toll-6-D42 has NMJ bouton | third instar larval stage phenotype, suppressible by Fmr1UAS.YFP, Scer\GAL4Toll-6-D42
Hsap\TARDBPUAS.YFP.cEa, Scer\GAL4GMR.PU has eye | adult stage phenotype, suppressible by Fmr1UAS.YFP, Scer\GAL4GMR.PU
Hsap\TARDBPUAS.YFP.cEa, Scer\GAL4Toll-6-D42 has NMJ bouton | larval stage phenotype, suppressible by futschEP1419, Scer\GAL4Toll-6-D42
Hsap\TARDBPUAS.YFP.cEa, Scer\GAL4GMR.PF has eye | heat sensitive phenotype, suppressible | partially by Hsap\HSPA1LUAS.cWa, Scer\GAL4GMR.PF
Hsap\TARDBPUAS.YFP.cEa, Scer\GAL4GMR.PF has eye | heat sensitive phenotype, suppressible | partially by BacA\p35UAS.cHa, Scer\GAL4GMR.PF
Pabp255 enhances the neurodegeneration phenotype (visible as depigmentation of the eye) in flies with expression of Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa driven by Scer\GAL4GMR.PU.
Pabp255 significantly enhances locomotor dysfunction seen in larvae with expression of Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa driven by Scer\GAL4GMR.PU.
The depigmentation phenotype in the adult eye and the lengthened time it takes for larvae to roll over in a turning assay characteristic for animals expressing Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa under the control of Scer\GAL4GMR.PU or Scer\GAL4Toll-6-D42 respectively, are exacerbated further by co-expression of Fmr1GD1288 RNAi. However, co-expression of Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa and Fmr1GD1288 under the Scer\GAL4Toll-6-D42 driver is pupal stage lethal.
The depigmentation phenotype in the adult eye and the lengthened time it takes for larvae to roll over in a turning assay characteristic for animals expressing Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa under the control of Scer\GAL4GMR.PU or Scer\GAL4Toll-6-D42 respectively, are restored by co-expression of Fmr1Scer\UAS.T:Avic\GFP-YFP.
The short adult life span, the increased number of satellite boutons along with the reduction in the density of futsch positive loops on synaptic boutons on neuromuscular junctions of third instar larvae characteristic for animals expressing Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa under the control of Scer\GAL4Toll-6-D42 can be fully (satellite boutons) or partially (loops density on synaptic boutons, adult life span) rescued by co-expression of Fmr1Scer\UAS.T:Avic\GFP-YFP.
The depigmentation phenotype in the adult eye and the lengthened time it takes for larvae to roll over in a turning assay characteristic for animals expressing Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa under the control of Scer\GAL4GMR.PU or Scer\GAL4Toll-6-D42 respectively, are exacerbated further by combination with Fmr1Δ50M in heterozygous state.
Pioglitazone can no longer rescue the Scer\GAL4D42>Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa-dependent larval turning defects in a heterozygous Eip75BΔ51 genetic background.
Pioglitazone can no longer rescue the Scer\GAL4D42>Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa-dependent larval turning defects when Eip78CJF02258 is co-expressed.
Expression of futschHMS02000 does not suppress the larval turning phenotype seen when Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa is expressed under the control of Scer\GAL4D42, but the flies are lethal at the pupal stage.
Expression of futschEP1419 partially suppresses the larval turning and reduced lifespan phenotypes seen when Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa is expressed under the control of Scer\GAL4D42.
Expression of futschEP1419 fully suppresses the reduction in boutons compared with controls seen when Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa is expressed under the control of Scer\GAL4D42. The increase in satellite bouton number in the larval NMJ is suppressed to control levels.
Expression of TBPHGD6943 enhances the third instar larval locomotor defects seen when Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa is expressed in motor neurons under the control of Scer\GAL4D42.
Expression of Hsap\HSPA1LScer\UAS.cWa partially suppresses the eye pigmentation phenotype seen in 15 day old adults when Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa is expressed under the control of Scer\GAL4D42 at 25[o]C.
Expression of BacA\p35Scer\UAS.cHa partially suppresses the eye pigmentation phenotype seen in 15 day old adults when Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa is expressed under the control of Scer\GAL4D42 at 25[o]C.
Expression of Prosβ21.Scer\UAS enhances the eye pigmentation phenotype seen when Hsap\TARDBPScer\UAS.T:Avic\GFP-YFP.cEa is expressed under the control of Scer\GAL4GMR.PF. This enhancement is seen throughout adult life at 25[o]C.